Gossamer Bio's Q3 net loss widens to $48.2 mln

Reuters11-06

<a href="https://laohu8.com/S/GOSS">Gossamer Bio</a>'s Q3 net loss widens to $48.2 mln

Overview

Gossamer Bio Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024
Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024

Outlook

Company expects topline results from PROSERA Phase 3 Study in February 2026
First site activated for SERANATA Phase 3 Study in PH-ILD
Company's cash reserves expected to fund operations into 2027

Result Drivers

R&D EXPENSES - Increase in R&D expenses to $45.5 mln from $34.9 mln in 2024 due to ongoing clinical trials
COLLABORATION REVENUE - Revenue from collaboration with Chiesi increased to $13.3 mln from $9.5 mln in 2024

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.21
Q3 Net Income		-$48.22 mln
Q3 Basic EPS		-$0.21
Q3 Operating Expenses		$62.41 mln
Q3 Operating Income		-$49.11 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Gossamer Bio Inc is $9.00, about 74.4% above its November 4 closing price of $2.30

Press Release: ID:nBw46f6tta

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581702646?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581702646","market":"nz","top_or_hot":-1,"title":"Gossamer Bio's Q3 net loss widens to $48.2 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/GOSS\">Gossamer Bio</a>'s Q3 net loss widens to $48.2 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Gossamer Bio Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024</p></li><li><p>Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects topline results from PROSERA Phase 3 Study in February 2026</p></li><li><p>First site activated for SERANATA Phase 3 Study in PH-ILD</p></li><li><p>Company's cash reserves expected to fund operations into 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses to $45.5 mln from $34.9 mln in 2024 due to ongoing clinical trials</p></li><li><p>COLLABORATION REVENUE - Revenue from collaboration with Chiesi increased to $13.3 mln from $9.5 mln in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$48.22 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$62.41 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$49.11 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Gossamer Bio Inc is $9.00, about 74.4% above its November 4 closing price of $2.30</p></li></ul><p>Press Release: <span>ID:nBw46f6tta</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gossamer Bio's Q3 net loss widens to $48.2 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGossamer Bio's Q3 net loss widens to $48.2 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/GOSS\">Gossamer Bio</a>'s Q3 net loss widens to $48.2 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Gossamer Bio Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024</p></li><li><p>Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects topline results from PROSERA Phase 3 Study in February 2026</p></li><li><p>First site activated for SERANATA Phase 3 Study in PH-ILD</p></li><li><p>Company's cash reserves expected to fund operations into 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>R&amp;D EXPENSES - Increase in R&amp;D expenses to $45.5 mln from $34.9 mln in 2024 due to ongoing clinical trials</p></li><li><p>COLLABORATION REVENUE - Revenue from collaboration with Chiesi increased to $13.3 mln from $9.5 mln in 2024</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$48.22 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-$0.21</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$62.41 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-$49.11 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Gossamer Bio Inc is $9.00, about 74.4% above its November 4 closing price of $2.30</p></li></ul><p>Press Release: <span>ID:nBw46f6tta</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1DH:1","article_id":"2581702646","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581702646","pubTimestamp":1762377820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gossamer Bio's Q3 net loss widens to $48.2 mlnOverviewGossamer Bio Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GOSS":"Gossamer Bio Inc.","BK4505":"高瓴资本持仓"},"translate_title":"Gossamer Bio第三季度净亏损扩大至4820万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GOSS":0.9},"content_text":"Gossamer Bio's Q3 net loss widens to $48.2 mlnOverviewGossamer Bio Q3 revenue from collaborations rises to $13.3 mln, up from $9.5 mln in 2024Net loss for Q3 widens to $48.2 mln from $30.8 mln in 2024OutlookCompany expects topline results from PROSERA Phase 3 Study in February 2026First site activated for SERANATA Phase 3 Study in PH-ILDCompany's cash reserves expected to fund operations into 2027Result DriversR&D EXPENSES - Increase in R&D expenses to $45.5 mln from $34.9 mln in 2024 due to ongoing clinical trialsCOLLABORATION REVENUE - Revenue from collaboration with Chiesi increased to $13.3 mln from $9.5 mln in 2024Key DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.21Q3 Net Income-$48.22 mlnQ3 Basic EPS-$0.21Q3 Operating Expenses$62.41 mlnQ3 Operating Income-$49.11 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 8 \"strong buy\" or \"buy\", 1 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Gossamer Bio Inc is $9.00, about 74.4% above its November 4 closing price of $2.30Press Release: ID:nBw46f6ttaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581702646","isCrawlerRequest":true}